Advances in CAR T Therapy for Hematologic Malignancies. Issue 8 (3rd June 2020)

• Record Type: Journal Article
• Authors: Freyer, Craig W.; Porter, David L.
• Other Names: Perkins Janelle guestEditor.; Koeller Jim guestEditor.
• Is Part Of: Pharmacotherapy. Volume 40:Issue 8(2020)
• Page Start: 741
• Page End: 755
• Publication Date: 2020-06-03
• Subjects: chimeric antigen receptor -- acute lymphoblastic leukemia -- non‐Hodgkin lymphoma -- multiple myeloma -- cytokine release syndrome; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2414
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract : The introduction of chimeric antigen receptor T‐cell (CAR T) therapy has resulted in a paradigm shift in the management of relapsed/refractory B‐cell malignancies. Patients with acute lymphoblastic leukemia and non‐Hodgkin's lymphoma who had exhausted all meaningful treatment options now have an opportunity for long‐term remission and possibly cure. CAR T is rapidly expanding into the treatment paradigm for multiple myeloma with approvals expected in the near future. CAR T for chronic lymphocytic leukemia may not be far behind, while CAR T studies in Hodgkin lymphoma and acute myeloid leukemia are ongoing. Such therapeutic success brings challenges in toxicity management related to cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome. Our understanding of these unique syndromes is evolving, with predictive models and additional treatment strategies on the horizon. This review aims to summarize the progress of CAR T therapeutics within malignant hematology thus far and highlight ongoing advances in the field.